业绩总结 - 2024年第一季度公司总收入为884亿美元，同比增长3.7%[6] - 调整后每股收益（EPS）为1.31美元，较2023年第一季度的2.20美元下降[6] - 2024年调整后每股收益指导下调至至少7.00美元[7] - 2024年第一季度运营现金流为49亿美元[3] - 2024年预计总收入至少为3690亿美元[7] - 2024年调整后运营收入指导下调至至少147.5亿美元[7] 用户数据 - 医疗保险业务的总收入为322亿美元，同比增长24.5%[10] - 药品和消费者健康部门的总收入为287亿美元，同比增长2.9%[12] - 健康服务部门的总收入为403亿美元，同比下降9.7%[11] 成本与支出 - 医疗成本超过预期，主要由于医疗优势计划的支出，导致医疗福利比率（MBR）为90.4%[10]

The shares of CVS Health Corp (NYSE:CVS) are plummeting today, down 18% at $55.55 at last glance and earlier as low as $54.04. The company announced first-quarter earnings and revenue that missed estimates, and slashed its 2024 forecast due to higher medical costs. Gapping to four-year lows, CVS is on track for its worst daily percentage drop since 2009. CVS Stock was already on a downtrend headed into today, below all moving averages between the 20- and 320-day trendlines. Since the start of the year, the ...

For the quarter ended March 2024, CVS Health (CVS) reported revenue of $88.44 billion, up 3.7% over the same period last year. EPS came in at $1.31, compared to $2.20 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $89.2 billion, representing a surprise of -0.86%. The company delivered an EPS surprise of -22.49%, with the consensus EPS estimate being $1.69.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street exp ...

CVS Health (CVS) came out with quarterly earnings of $1.31 per share, missing the Zacks Consensus Estimate of $1.69 per share. This compares to earnings of $2.20 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -22.49%. A quarter ago, it was expected that this drugstore chain and pharmacy benefits manager would post earnings of $2.01 per share when it actually produced earnings of $2.12, delivering a surprise of 5.47%.Over the ...

Key TakeawaysCVS shares tumbled Wednesday following the release of first-quarter results that missed analysts' expectations.The retail pharmacy giant also lowered its full-year guidance for earnings per share.Profits were hit as health care costs rose and CVS said Medicare utilization increased.CVS has struggled with having to pay out more to policyholders of its health insurance businesses as many people underwent procedures they may have delayed during the pandemic. CVS Health (CVS) shares tumbled close t ...

CVS Health on Wednesday reported first-quarter revenue and adjusted earnings that missed expectations and slashed its full-year profit outlook, citing higher medical costs that are dogging the U.S. insurance industry.Shares of the company dropped 10% in premarket trading.The drugstore chain expects 2024 adjusted earnings of at least $7 per share, down from a previous guidance of at least $8.30 per share. Analysts surveyed by LSEG were expecting full-year adjusted profit of $8.28 per share. CVS also cut its ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to_________ Commission File Number: 001-01011 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 05-0494040 (Sta ...

Exhibit 99.1 CVS HEALTH CORPORATION REPORTS FIRST QUARTER 2024 RESULTS AND REVISES FULL-YEAR 2024 GUIDANCE First Quarter Highlights • Total revenues increased to $88.4 billion, up 3.7% compared to prior year • GAAP diluted EPS of $0.88 and Adjusted EPS of $1.31 • Generated cash flow from operations of $4.9 billion 2024 Full-Year Guidance • Revised GAAP diluted EPS guidance to at least $5.64 from at least $7.06 • Revised Adjusted EPS guidance to at least $7.00 from at least $8.30 • Revised cash flow from ope ...

First Quarter Highlights Total revenues increased to $88.4 billion, up 3.7% compared to prior year GAAP diluted EPS of $0.88 and Adjusted EPS of $1.31 Generated cash flow from operations of $4.9 billion 2024 Full-Year Guidance Revised GAAP diluted EPS guidance to at least $5.64 from at least $7.06 Revised Adjusted EPS guidance to at least $7.00 from at least $8.30 Revised cash flow from operations guidance to at least $10.5 billion from at least $12.0 billion CEO Commentary"The current environment does not ...

Key PointsCVS Stock trades near a 52-week low, allowing investors to build a potential bull case. Compared to its closest competitor, Walgreens, CVS still holds more market share, and markets reward this. Financials back analysts' EPS projections and price targets to give investors the upside they could be hunting for.5 stocks we like better than UBS GroupAfter underperforming its peers in the healthcare sector, shares of CVS Health Co. NYSE: CVS are now nearing a 52-week low price. Underperforming the Heal ...